{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,27]],"date-time":"2026-10-27T21:36:39Z","timestamp":1793136999232,"version":"4.5.0"},"reference-count":148,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2027,10,19]],"date-time":"2027-10-19T00:00:00Z","timestamp":1823904000000},"content-version":"am","delay-in-days":352,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"funder":[{"DOI":"10.13039\/100000054","name":"National Cancer Institute","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","jaad.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of the American Academy of Dermatology"],"published-print":{"date-parts":[[2026,11]]},"DOI":"10.1016\/j.jaad.2026.06.126","type":"journal-article","created":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T23:32:55Z","timestamp":1782948775000},"page":"1386-1398","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Perioperative management of dermatologic surgery patients on systemic cancer therapy"],"prefix":"10.1016","volume":"95","author":[{"given":"Megan H.","family":"Trager","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emily R.","family":"Gordon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chelsea","family":"Handfield","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anuja","family":"Kriplani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"James","family":"Smithy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anthony","family":"Rossi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Erica","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kishwer","family":"Nehal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karen","family":"Connolly","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jaad.2026.06.126_bib1","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1016\/j.jaad.2025.03.006","article-title":"Improved survival at the population level for patients with advanced Merkel cell carcinoma following availability of immunotherapy","volume":"93","author":"Paulson","year":"2025","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.jaad.2026.06.126_bib2","doi-asserted-by":"crossref","DOI":"10.1002\/cncr.35476","article-title":"Survival trends among patients with metastatic non-small cell lung cancer before and after the approval of immunotherapy in the United States: a Surveillance, Epidemiology, and End Results database-based study","volume":"131","author":"Wang","year":"2025","journal-title":"Cancer"},{"key":"10.1016\/j.jaad.2026.06.126_bib42","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1016\/j.jaad.2024.01.096","article-title":"Part 1: management of antithrombotic medications in dermatologic surgery","volume":"92","author":"Trager","year":"2025","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.jaad.2026.06.126_bib85","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1007\/978-3-031-27156-4_10","article-title":"Targeted therapy and personalized medicine","volume":"185","author":"Saeed","year":"2023","journal-title":"Cancer Treat Res"},{"key":"10.1016\/j.jaad.2026.06.126_bib3","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1016\/j.canep.2012.11.001","article-title":"Selected adverse events in cancer patients treated with vascular endothelial growth factor inhibitors","volume":"37","author":"Dreyfus","year":"2013","journal-title":"Cancer Epidemiol"},{"key":"10.1016\/j.jaad.2026.06.126_bib4","doi-asserted-by":"crossref","first-page":"432","DOI":"10.1634\/theoncologist.2010-0271","article-title":"Noncardiac vascular toxicities of vascular endothelial growth factor inhibitors in advanced cancer: a review","volume":"16","author":"Keefe","year":"2011","journal-title":"Oncologist"},{"key":"10.1016\/j.jaad.2026.06.126_bib5","first-page":"1445","article-title":"Vascular endothelial growth factor mediates angiogenic activity during the proliferative phase of wound healing","volume":"152","author":"Nissen","year":"1998","journal-title":"Am J Pathol"},{"key":"10.1016\/j.jaad.2026.06.126_bib73","series-title":"Sorafenib [Package Insert]","year":"2005"},{"key":"10.1016\/j.jaad.2026.06.126_bib74","first-page":"243","article-title":"Cutaneous side effects of inhibition of VEGF signal transduction","volume":"8","author":"Wozel","year":"2010","journal-title":"J Dtsch Dermatol Ges"},{"key":"10.1016\/j.jaad.2026.06.126_bib6","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1016\/S1470-2045(09)70341-9","article-title":"Vascular endothelial growth factor targeted therapy in the perioperative setting: implications for patient care","volume":"11","author":"Bose","year":"2010","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.jaad.2026.06.126_bib7","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1006\/jsre.2002.6444","article-title":"Vascular endothelial growth factor-mediated angiogenesis inhibition and postoperative wound healing in rats","volume":"105","author":"Roman","year":"2002","journal-title":"J Surg Res"},{"key":"10.1016\/j.jaad.2026.06.126_bib8","doi-asserted-by":"crossref","first-page":"707","DOI":"10.1097\/SAP.0b013e3181828141","article-title":"A review on bevacizumab and surgical wound healing: an important warning to all surgeons","volume":"62","author":"Gordon","year":"2009","journal-title":"Ann Plast Surg"},{"key":"10.1016\/j.jaad.2026.06.126_bib9","series-title":"Bevacizumab [Package Insert]","year":"2022"},{"key":"10.1016\/j.jaad.2026.06.126_bib10","series-title":"Pazopanib [Package Insert]","year":"2023"},{"key":"10.1016\/j.jaad.2026.06.126_bib11","doi-asserted-by":"crossref","first-page":"583","DOI":"10.25259\/SNI_959_2022","article-title":"Timing of bevacizumab administration after biopsy for unresectable newly diagnosed glioblastoma","volume":"13","author":"Matsuda","year":"2022","journal-title":"Surg Neurol Int"},{"key":"10.1016\/j.jaad.2026.06.126_bib12","series-title":"Sunitinib [Package Insert]","year":"2021"},{"key":"10.1016\/j.jaad.2026.06.126_bib13","doi-asserted-by":"crossref","first-page":"716","DOI":"10.1200\/JCO.24.01034","article-title":"ReNeu: a pivotal, phase IIb trial of mirdametinib in adults and children with symptomatic neurofibromatosis type 1-Associated plexiform neurofibroma","volume":"43","author":"Moertel","year":"2025","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.jaad.2026.06.126_bib14","series-title":"MEKINIST (Trametinib) [Package Insert]","year":"2013"},{"key":"10.1016\/j.jaad.2026.06.126_bib15","series-title":"COTELLIC (Cobimetinib) [Package Insert]","year":"2015"},{"key":"10.1016\/j.jaad.2026.06.126_bib16","first-page":"610","article-title":"Mucocutaneous toxicities from MEK inhibitors: a scoping review of the literature","volume":"32","author":"Iriarte","year":"2024","journal-title":"Support Care Cancer"},{"key":"10.1016\/j.jaad.2026.06.126_bib17","doi-asserted-by":"crossref","first-page":"3307","DOI":"10.2217\/fon.15.265","article-title":"Risk of selected dermatological toxicities in cancer patients treated with MEK inhibitors: a comparative systematic review and meta-analysis","volume":"11","author":"Abdel-Rahman","year":"2015","journal-title":"Future Oncol"},{"key":"10.1016\/j.jaad.2026.06.126_bib18","doi-asserted-by":"crossref","first-page":"762","DOI":"10.1080\/09537104.2018.1514107","article-title":"Cobimetinib and trametinib inhibit platelet MEK but do not cause platelet dysfunction","volume":"30","author":"Unsworth","year":"2019","journal-title":"Platelets"},{"key":"10.1016\/j.jaad.2026.06.126_bib19","doi-asserted-by":"crossref","first-page":"1036","DOI":"10.1089\/thy.2019.0133","article-title":"Complete surgical resection following neoadjuvant dabrafenib plus trametinib in BRAF(V600E)-mutated anaplastic thyroid carcinoma","volume":"29","author":"Wang","year":"2019","journal-title":"Thyroid"},{"key":"10.1016\/j.jaad.2026.06.126_bib20","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1016\/S1470-2045(18)30015-9","article-title":"Neoadjuvant plus adjuvant dabrafenib and trametinib versus standard of care in patients with high-risk, surgically resectable melanoma: a single-centre, open-label, randomised, phase 2 trial","volume":"19","author":"Amaria","year":"2018","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.jaad.2026.06.126_bib21","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2024.1504142","article-title":"The evolution of BRAF-targeted therapies in melanoma: overcoming hurdles and unleashing novel strategies","volume":"14","author":"Imani","year":"2024","journal-title":"Front Oncol"},{"key":"10.1016\/j.jaad.2026.06.126_bib76","doi-asserted-by":"crossref","first-page":"1103","DOI":"10.1001\/jamadermatol.2015.1745","article-title":"Cutaneous toxic effects of BRAF inhibitors alone and in combination with MEK inhibitors for metastatic melanoma","volume":"151","author":"Carlos","year":"2015","journal-title":"JAMA Dermatol"},{"key":"10.1016\/j.jaad.2026.06.126_bib22","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2022.827985","article-title":"Adverse effects of vemurafenib on skin integrity: hyperkeratosis and skin cancer initiation due to altered MEK\/ERK-signaling and MMP activity","volume":"12","author":"Tham","year":"2022","journal-title":"Front Oncol"},{"key":"10.1016\/j.jaad.2026.06.126_bib23","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1002\/cncr.28980","article-title":"Clinico-morphological features of BRAF inhibition-induced proliferative skin lesions in cancer patients","volume":"121","author":"Belum","year":"2015","journal-title":"Cancer"},{"key":"10.1016\/j.jaad.2026.06.126_bib24","doi-asserted-by":"crossref","first-page":"400","DOI":"10.1007\/s00403-024-03139-1","article-title":"Intralesional methotrexate versus 5-flurouracil in the treatment of keratoacanthoma","volume":"316","author":"Nofal","year":"2024","journal-title":"Arch Dermatol Res"},{"issue":"Suppl 1","key":"10.1016\/j.jaad.2026.06.126_bib25","doi-asserted-by":"crossref","first-page":"S40","DOI":"10.1097\/DSS.0000000000000519","article-title":"Managing cutaneous side effects from targeted molecular inhibitors for melanoma and nonmelanoma skin cancer","volume":"42","author":"Tang","year":"2016","journal-title":"Dermatol Surg"},{"key":"10.1016\/j.jaad.2026.06.126_bib26","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1007\/s00403-024-03785-5","article-title":"The paradoxical activity of BRAF inhibitors: potential use in wound healing","volume":"317","author":"Karhana","year":"2025","journal-title":"Arch Dermatol Res"},{"key":"10.1016\/j.jaad.2026.06.126_bib27","series-title":"TAFINLAR (Dabrafenib)","year":"2013"},{"key":"10.1016\/j.jaad.2026.06.126_bib28","doi-asserted-by":"crossref","first-page":"1877","DOI":"10.1056\/NEJMoa1406037","article-title":"Combined BRAF and MEK inhibition versus BRAF inhibition alone in melanoma","volume":"371","author":"Long","year":"2014","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jaad.2026.06.126_bib29","doi-asserted-by":"crossref","first-page":"316","DOI":"10.1200\/JCO.2011.36.7680","article-title":"RAS mutations are associated with the development of cutaneous squamous cell tumors in patients treated with RAF inhibitors","volume":"30","author":"Oberholzer","year":"2012","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.jaad.2026.06.126_bib30","doi-asserted-by":"crossref","first-page":"1694","DOI":"10.1056\/NEJMoa1210093","article-title":"Combined BRAF and MEK inhibition in melanoma with BRAF V600 mutations","volume":"367","author":"Flaherty","year":"2012","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jaad.2026.06.126_bib31","doi-asserted-by":"crossref","first-page":"484","DOI":"10.1089\/thy.2022.0504","article-title":"Surgery after BRAF-directed therapy is associated with improved survival in BRAF(V600E) mutant anaplastic thyroid cancer: a single-center retrospective cohort study","volume":"33","author":"Zhao","year":"2023","journal-title":"Thyroid"},{"key":"10.1016\/j.jaad.2026.06.126_bib32","doi-asserted-by":"crossref","first-page":"938","DOI":"10.3390\/cancers12040938","article-title":"BCL-2 proteins in pathogenesis and therapy of B-cell non-hodgkin lymphomas","volume":"12","author":"Klanova","year":"2020","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.jaad.2026.06.126_bib33","series-title":"VENETOCLAX (VENCLEXTA) [Package Insert]","year":"2016"},{"key":"10.1016\/j.jaad.2026.06.126_bib34","doi-asserted-by":"crossref","first-page":"1739","DOI":"10.1056\/NEJMoa2213093","article-title":"First-line venetoclax combinations in chronic lymphocytic leukemia","volume":"388","author":"Eichhorst","year":"2023","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jaad.2026.06.126_bib77","doi-asserted-by":"crossref","first-page":"170","DOI":"10.1001\/jamadermatol.2014.2734","article-title":"Cutaneous adverse effects associated with the tyrosine-kinase inhibitor cabozantinib","volume":"151","author":"Zuo","year":"2015","journal-title":"JAMA Dermatol"},{"key":"10.1016\/j.jaad.2026.06.126_bib35","series-title":"Cabozantinib [Package Insert]","year":"2016"},{"key":"10.1016\/j.jaad.2026.06.126_bib36","series-title":"Inlyta (Axitinib) [Package Insert]","year":"2012"},{"key":"10.1016\/j.jaad.2026.06.126_bib37","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1097\/DSS.0000000000003650","article-title":"Severe postoperative bleeding secondary to ibrutinib intake","volume":"49","author":"Llull-Ramos","year":"2023","journal-title":"Dermatol Surg"},{"key":"10.1016\/j.jaad.2026.06.126_bib38","series-title":"Ibrutinib [Package Insert]","year":"2025"},{"key":"10.1016\/j.jaad.2026.06.126_bib75","doi-asserted-by":"crossref","first-page":"799","DOI":"10.1007\/s40257-020-00535-x","article-title":"Dermatological toxicities of Bruton's tyrosine kinase inhibitors","volume":"21","author":"Sibaud","year":"2020","journal-title":"Am J Clin Dermatol"},{"key":"10.1016\/j.jaad.2026.06.126_bib39","doi-asserted-by":"crossref","first-page":"1069","DOI":"10.1001\/jamadermatol.2017.1877","article-title":"Association of ibrutinib treatment with bleeding complications in cutaneous surgery","volume":"153","author":"Parra","year":"2017","journal-title":"JAMA Dermatol"},{"key":"10.1016\/j.jaad.2026.06.126_bib40","doi-asserted-by":"crossref","first-page":"1","DOI":"10.5070\/D328659727","article-title":"Bleeding complication following a shave biopsy in a patient taking ibrutinib","volume":"28","author":"Esfandiari","year":"2022","journal-title":"Dermatol Online J"},{"key":"10.1016\/j.jaad.2026.06.126_bib41","doi-asserted-by":"crossref","first-page":"1554","DOI":"10.1038\/s41375-023-01869-1","article-title":"Evaluation of bleeding events in patients receiving acalabrutinib therapy","volume":"37","author":"Kumar","year":"2023","journal-title":"Leukemia"},{"key":"10.1016\/j.jaad.2026.06.126_bib43","doi-asserted-by":"crossref","first-page":"3958","DOI":"10.1158\/1078-0432.CCR-08-2785","article-title":"Clinical studies of histone deacetylase inhibitors","volume":"15","author":"Prince","year":"2009","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.jaad.2026.06.126_bib44","doi-asserted-by":"crossref","first-page":"2751","DOI":"10.3390\/ph3092751","article-title":"Clinical toxicities of histone deacetylase inhibitors","volume":"3","author":"Subramanian","year":"2010","journal-title":"Pharmaceuticals (Basel)"},{"key":"10.1016\/j.jaad.2026.06.126_bib45","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1200\/JCO.2017.76.1734","article-title":"Platelet transfusion for patients with cancer: American Society of Clinical Oncology clinical practice guideline update","volume":"36","author":"Schiffer","year":"2017","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.jaad.2026.06.126_bib46","doi-asserted-by":"crossref","first-page":"2651","DOI":"10.3390\/ijms24032651","article-title":"Small molecule EGFR inhibitors as anti-cancer agents: discovery, mechanisms of action, and opportunities","volume":"24","author":"Zubair","year":"2023","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.jaad.2026.06.126_bib78","series-title":"TARCEVA (Erlotinib) [Package Insert]","year":"2004"},{"key":"10.1016\/j.jaad.2026.06.126_bib79","series-title":"ERBITUX (Cetuximab) [Package Insert]","year":"2021"},{"key":"10.1016\/j.jaad.2026.06.126_bib47","doi-asserted-by":"crossref","DOI":"10.2340\/actadv.v104.40555","article-title":"Skin toxicities induced by epidermal growth factor receptor tyrosine kinase inhibitors and their influence on treatment adjustments in lung cancer patients","volume":"104","author":"Lee","year":"2024","journal-title":"Acta Derm Venereol"},{"key":"10.1016\/j.jaad.2026.06.126_bib48","doi-asserted-by":"crossref","first-page":"657","DOI":"10.1016\/j.jaad.2005.10.010","article-title":"Dermatologic side effects associated with the epidermal growth factor receptor inhibitors","volume":"55","author":"Agero","year":"2006","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.jaad.2026.06.126_bib49","doi-asserted-by":"crossref","DOI":"10.3390\/ijms222212244","article-title":"Safety of surgery after neoadjuvant targeted therapies in non-small cell lung cancer: a narrative review","volume":"22","author":"Marjanski","year":"2021","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.jaad.2026.06.126_bib71","doi-asserted-by":"crossref","first-page":"935","DOI":"10.1001\/jamaoto.2022.2291","article-title":"Association of neoadjuvant pembrolizumab for oral cavity squamous cell carcinoma with adverse events after surgery in treatment-naive patients","volume":"148","author":"Tang","year":"2022","journal-title":"JAMA Otolaryngol Head Neck Surg"},{"key":"10.1016\/j.jaad.2026.06.126_bib69","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1056\/NEJMra1703481","article-title":"Immune-related adverse events associated with immune checkpoint blockade","volume":"378","author":"Postow","year":"2018","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jaad.2026.06.126_bib70","doi-asserted-by":"crossref","first-page":"4073","DOI":"10.1200\/JCO.21.01440","article-title":"Management of immune-related adverse events in patients treated with immune checkpoint inhibitor therapy: ASCO guideline update","volume":"39","author":"Schneider","year":"2021","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.jaad.2026.06.126_bib72","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1007\/s11912-022-01202-6","article-title":"Cancer immunotherapies: what the perioperative physician needs to know","volume":"24","author":"Ackerman","year":"2022","journal-title":"Curr Oncol Rep"},{"key":"10.1016\/j.jaad.2026.06.126_bib53","doi-asserted-by":"crossref","first-page":"2531","DOI":"10.1056\/NEJMoa1707447","article-title":"Axicabtagene ciloleucel CAR T-cell therapy in refractory large B-cell lymphoma","volume":"377","author":"Neelapu","year":"2017","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jaad.2026.06.126_bib54","doi-asserted-by":"crossref","first-page":"897","DOI":"10.1186\/s12967-024-05703-9","article-title":"TCR-T cell therapy: current development approaches, preclinical evaluation, and perspectives on regulatory challenges","volume":"22","author":"Golikova","year":"2024","journal-title":"J Transl Med"},{"key":"10.1016\/j.jaad.2026.06.126_bib55","doi-asserted-by":"crossref","first-page":"530","DOI":"10.1038\/s41422-022-00627-9","article-title":"Defined tumor antigen-specific T cells potentiate personalized TCR-T cell therapy and prediction of immunotherapy response","volume":"32","author":"He","year":"2022","journal-title":"Cell Res"},{"key":"10.1016\/j.jaad.2026.06.126_bib56","doi-asserted-by":"crossref","first-page":"2656","DOI":"10.1200\/JCO.21.00612","article-title":"Lifileucel, a tumor-infiltrating lymphocyte therapy, in metastatic melanoma","volume":"39","author":"Sarnaik","year":"2021","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.jaad.2026.06.126_bib57","doi-asserted-by":"crossref","DOI":"10.1016\/j.critrevonc.2025.104671","article-title":"Outcomes of tumor-infiltrating lymphocyte therapy in solid tumours - a systematic review and meta analysis","volume":"209","author":"Mony","year":"2025","journal-title":"Crit Rev Oncol Hematol"},{"key":"10.1016\/j.jaad.2026.06.126_bib110","doi-asserted-by":"crossref","first-page":"2545","DOI":"10.1056\/NEJMoa1708566","article-title":"Chimeric antigen receptor T cells in refractory B-cell lymphomas","volume":"377","author":"Schuster","year":"2017","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jaad.2026.06.126_bib111","doi-asserted-by":"crossref","first-page":"5233","DOI":"10.1200\/JCO.2008.16.5449","article-title":"Adoptive cell therapy for patients with metastatic melanoma: evaluation of intensive myeloablative chemoradiation preparative regimens","volume":"26","author":"Dudley","year":"2008","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.jaad.2026.06.126_bib112","doi-asserted-by":"crossref","first-page":"597","DOI":"10.1016\/j.jaad.2021.07.017","article-title":"Cutaneous manifestations of chimeric antigen receptor T-cell therapy: an introduction for dermatologists","volume":"87","author":"Nusbaum","year":"2022","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.jaad.2026.06.126_bib113","doi-asserted-by":"crossref","first-page":"1035.e1","DOI":"10.1016\/j.jtct.2024.06.024","article-title":"Dermatologic adverse events associated with chimeric antigen receptor T-Cell therapy: a pharmacovigilance analysis of the FDA reporting system","volume":"30","author":"Storgard","year":"2024","journal-title":"Transplant Cell Ther"},{"key":"10.1016\/j.jaad.2026.06.126_bib114","doi-asserted-by":"crossref","first-page":"981","DOI":"10.1016\/j.ophtha.2008.12.004","article-title":"Ocular and systemic autoimmunity after successful tumor-infiltrating lymphocyte immunotherapy for recurrent, metastatic melanoma","volume":"116","author":"Yeh","year":"2009","journal-title":"Ophthalmology"},{"key":"10.1016\/j.jaad.2026.06.126_bib58","doi-asserted-by":"crossref","first-page":"2414","DOI":"10.1111\/bcp.14403","article-title":"Chimeric antigen receptor T-cell therapy toxicities","volume":"87","author":"Greenbaum","year":"2021","journal-title":"Br J Clin Pharmacol"},{"key":"10.1016\/j.jaad.2026.06.126_bib59","doi-asserted-by":"crossref","first-page":"1924","DOI":"10.1001\/jama.2024.19462","article-title":"CAR T cells and T-cell therapies for cancer: a translational science review","volume":"332","author":"Brudno","year":"2024","journal-title":"JAMA"},{"key":"10.1016\/j.jaad.2026.06.126_bib60","doi-asserted-by":"crossref","first-page":"7140","DOI":"10.1038\/s41598-022-10777-w","article-title":"Adverse events associated with JAK inhibitors in 126,815 reports from the WHO pharmacovigilance database","volume":"12","author":"Hoisnard","year":"2022","journal-title":"Sci Rep"},{"key":"10.1016\/j.jaad.2026.06.126_bib61","doi-asserted-by":"crossref","first-page":"534","DOI":"10.1016\/j.jaad.2022.11.043","article-title":"Risk of melanoma and nonmelanoma skin cancer with immunosuppressants, part II: methotrexate, alkylating agents, biologics, and small molecule inhibitors","volume":"88","author":"Kreher","year":"2023","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.jaad.2026.06.126_bib62","doi-asserted-by":"crossref","first-page":"204","DOI":"10.5021\/ad.2019.31.2.204","article-title":"Rapidly growing and aggressive cutaneous squamous cell carcinomas in a patient treated with ruxolitinib","volume":"31","author":"March-Rodriguez","year":"2019","journal-title":"Ann Dermatol"},{"key":"10.1016\/j.jaad.2026.06.126_bib63","doi-asserted-by":"crossref","first-page":"1339","DOI":"10.1001\/jamadermatol.2023.3830","article-title":"Janus kinase inhibitors and adverse events of acne: a systematic review and meta-analysis","volume":"159","author":"Martinez","year":"2023","journal-title":"JAMA Dermatol"},{"key":"10.1016\/j.jaad.2026.06.126_bib64","doi-asserted-by":"crossref","first-page":"1037","DOI":"10.1038\/s41416-020-01225-5","article-title":"Overcoming the challenges associated with CD3+ T-cell redirection in cancer","volume":"124","author":"Singh","year":"2021","journal-title":"Br J Cancer"},{"key":"10.1016\/j.jaad.2026.06.126_bib65","doi-asserted-by":"crossref","first-page":"3192","DOI":"10.1002\/cncr.32909","article-title":"The BiTE (bispecific T-cell engager) platform: development and future potential of a targeted immuno-oncology therapy across tumor types","volume":"126","author":"Einsele","year":"2020","journal-title":"Cancer"},{"key":"10.1016\/j.jaad.2026.06.126_bib66","doi-asserted-by":"crossref","first-page":"392","DOI":"10.1093\/ced\/llad387","article-title":"Cutaneous adverse effects induced by tebentafusp in patients with metastatic uveal melanoma: a case series and treatment insights","volume":"49","author":"Rodriguez","year":"2024","journal-title":"Clin Exp Dermatol"},{"key":"10.1016\/j.jaad.2026.06.126_bib67","doi-asserted-by":"crossref","first-page":"1583","DOI":"10.1080\/10428194.2023.2221756","article-title":"Dermatologic adverse events in acute lymphocytic leukemia patients treated with bispecific T-cell engager blinatumomab","volume":"64","author":"Parisi","year":"2023","journal-title":"Leuk Lymphoma"},{"key":"10.1016\/j.jaad.2026.06.126_bib68","doi-asserted-by":"crossref","first-page":"1366","DOI":"10.1634\/theoncologist.2018-0179","article-title":"FDA supplemental approval: blinatumomab for treatment of relapsed and refractory precursor B-cell acute lymphoblastic leukemia","volume":"23","author":"Pulte","year":"2018","journal-title":"Oncologist"},{"key":"10.1016\/j.jaad.2026.06.126_bib50","doi-asserted-by":"crossref","first-page":"549","DOI":"10.1056\/NEJMoa041668","article-title":"Efficacy of lenalidomide in myelodysplastic syndromes","volume":"352","author":"List","year":"2005","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jaad.2026.06.126_bib51","doi-asserted-by":"crossref","first-page":"2079","DOI":"10.1056\/NEJMc053530","article-title":"Lenalidomide and venous thrombosis in multiple myeloma","volume":"354","author":"Knight","year":"2006","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jaad.2026.06.126_bib115","doi-asserted-by":"crossref","first-page":"1298","DOI":"10.1001\/archderm.142.10.1298","article-title":"Dermatologic adverse effects of lenalidomide therapy for amyloidosis and multiple myeloma","volume":"142","author":"Sviggum","year":"2006","journal-title":"Arch Dermatol"},{"key":"10.1016\/j.jaad.2026.06.126_bib52","doi-asserted-by":"crossref","first-page":"1594","DOI":"10.1016\/j.jaad.2018.11.032","article-title":"A 4-year retrospective assessment of postoperative complications in immunosuppressed patients following Mohs micrographic surgery","volume":"80","author":"Basu","year":"2019","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.jaad.2026.06.126_bib86","series-title":"Abraxane (Paclitaxel) [Package Insert]","year":"2005"},{"key":"10.1016\/j.jaad.2026.06.126_bib88","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1684\/ejd.2016.2833","article-title":"Dermatological adverse events with taxane chemotherapy","volume":"26","author":"Sibaud","year":"2016","journal-title":"Eur J Dermatol"},{"key":"10.1016\/j.jaad.2026.06.126_bib90","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1089\/wound.2023.0097","article-title":"Chemotherapy-mediated complications of wound healing: an understudied side effect","volume":"13","author":"S\u0142onimska","year":"2024","journal-title":"Adv Wound Care (New Rochelle)"},{"key":"10.1016\/j.jaad.2026.06.126_bib92","doi-asserted-by":"crossref","first-page":"1117","DOI":"10.1080\/0284186X.2018.1449248","article-title":"Predictors for doxorubicin-induced hematological toxicity and its association with outcome in advanced soft tissue sarcoma patients; a retrospective analysis of the EORTC-soft tissue and bone sarcoma group database","volume":"57","author":"Sleijfer","year":"2018","journal-title":"Acta Oncol"},{"key":"10.1016\/j.jaad.2026.06.126_bib95","doi-asserted-by":"crossref","first-page":"3153","DOI":"10.1002\/1097-0142(19930515)71:10<3153::AID-CNCR2820711042>3.0.CO;2-#","article-title":"Dose-related cutaneous toxicities with etoposide","volume":"71","author":"Murphy","year":"1993","journal-title":"Cancer"},{"key":"10.1016\/j.jaad.2026.06.126_bib87","doi-asserted-by":"crossref","first-page":"1465","DOI":"10.1001\/jamadermatol.2018.3465","article-title":"Evaluation of prevention interventions for taxane-induced dermatologic adverse events: a systematic review","volume":"154","author":"Marks","year":"2018","journal-title":"JAMA Dermatol"},{"key":"10.1016\/j.jaad.2026.06.126_bib89","doi-asserted-by":"crossref","first-page":"6645","DOI":"10.1039\/C8DT00838H","article-title":"The side effects of platinum-based chemotherapy drugs: a review for chemists","volume":"47","author":"Oun","year":"2018","journal-title":"Dalton Trans"},{"key":"10.1016\/j.jaad.2026.06.126_bib91","series-title":"Doxil [Package Insert]","year":"1995"},{"key":"10.1016\/j.jaad.2026.06.126_bib93","series-title":"Cyclophosphamide [Package Insert]","year":"1959"},{"key":"10.1016\/j.jaad.2026.06.126_bib94","series-title":"Etoposide [Package Insert]","year":"1983"},{"key":"10.1016\/j.jaad.2026.06.126_bib96","series-title":"Xeloda (Capecitabine) [Package Insert]","year":"1998"},{"key":"10.1016\/j.jaad.2026.06.126_bib97","doi-asserted-by":"crossref","first-page":"166","DOI":"10.1111\/ced.12708","article-title":"Acral keratoses and leucocytoclastic vasculitis occurring during treatment of essential thrombocythaemia with hydroxyurea","volume":"41","author":"Worley","year":"2016","journal-title":"Clin Exp Dermatol"},{"key":"10.1016\/j.jaad.2026.06.126_bib98","doi-asserted-by":"crossref","first-page":"404","DOI":"10.1002\/cncr.26194","article-title":"Symptomatic mucocutaneous toxicity of hydroxyurea in Philadelphia chromosome-negative myeloproliferative neoplasms: the Mister Hyde face of a safe drug","volume":"118","author":"Latagliata","year":"2012","journal-title":"Cancer"},{"key":"10.1016\/j.jaad.2026.06.126_bib99","doi-asserted-by":"crossref","first-page":"372","DOI":"10.1016\/S0190-9622(98)70394-9","article-title":"Leg ulcers associated with long-term hydroxyurea therapy","volume":"39","author":"Weinlich","year":"1998","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.jaad.2026.06.126_bib100","first-page":"343","article-title":"Cutaneous ulcerations on hands and heels secondary to long-term hydroxyurea treatment","volume":"14","author":"Friedrich","year":"2004","journal-title":"Eur J Dermatol"},{"key":"10.1016\/j.jaad.2026.06.126_bib101","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1111\/j.1365-4632.2004.02450.x","article-title":"Leg ulcer in a patient associated with hydroxyurea therapy","volume":"45","author":"Dissemond","year":"2006","journal-title":"Int J Dermatol"},{"key":"10.1016\/j.jaad.2026.06.126_bib102","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1001\/jama.2024.20377","article-title":"Diagnosis and treatment of polycythemia vera: a review","volume":"333","author":"Tremblay","year":"2025","journal-title":"JAMA"},{"key":"10.1016\/j.jaad.2026.06.126_bib103","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1111\/j.1365-4632.2011.05105.x","article-title":"Hydroxyurea-induced dermatomyositis: true amyopathic dermatomyositis or dermatomyositis-like eruption?","volume":"51","author":"Nofal","year":"2012","journal-title":"Int J Dermatol"},{"key":"10.1016\/j.jaad.2026.06.126_bib104","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1067\/mjd.2003.74","article-title":"Hydroxyurea-induced dermatomyositis-like eruption","volume":"48","author":"Dacey","year":"2003","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.jaad.2026.06.126_bib105","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1001\/archdermatol.2010.11","article-title":"Hydroxyurea-associated dermatomyositis-like eruption demonstrating abnormal epidermal p53 expression: a potential premalignant manifestation of chronic hydroxyurea and UV radiation exposure","volume":"146","author":"Kalajian","year":"2010","journal-title":"Arch Dermatol"},{"key":"10.1016\/j.jaad.2026.06.126_bib106","doi-asserted-by":"crossref","first-page":"810","DOI":"10.1111\/ijd.15302","article-title":"Hydroxyurea: a reappraisal of its cutaneous side effects and their management","volume":"60","author":"Bulte","year":"2021","journal-title":"Int J Dermatol"},{"key":"10.1016\/j.jaad.2026.06.126_bib107","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1046\/j.1365-2230.2001.00782.x","article-title":"Muco-cutaneous changes during long-term therapy with hydroxyurea in chronic myeloid leukaemia","volume":"26","author":"Vassallo","year":"2001","journal-title":"Clin Exp Dermatol"},{"key":"10.1016\/j.jaad.2026.06.126_bib108","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1111\/j.0736-8046.2004.21207.x","article-title":"Cutaneous manifestations of hydroxyurea therapy in childhood: case report and review","volume":"21","author":"Issaivanan","year":"2004","journal-title":"Pediatr Dermatol"},{"key":"10.1016\/j.jaad.2026.06.126_bib109","doi-asserted-by":"crossref","first-page":"178","DOI":"10.1016\/S0190-9622(97)70276-7","article-title":"Hydroxyurea dermopathy: a unique lichenoid eruption complicating long-term therapy with hydroxyurea","volume":"36","author":"Daoud","year":"1997","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.jaad.2026.06.126_bib116","doi-asserted-by":"crossref","first-page":"897","DOI":"10.1016\/j.jaad.2006.06.030","article-title":"Pleomorphic presentation of cutaneous lesions associated with the proteasome inhibitor bortezomib in patients with multiple myeloma","volume":"55","author":"Wu","year":"2006","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.jaad.2026.06.126_bib117","first-page":"ECR44","article-title":"Skin lesions induced by bortezomib","volume":"90","author":"Pour","year":"2005","journal-title":"Haematologica"},{"key":"10.1016\/j.jaad.2026.06.126_bib118","doi-asserted-by":"crossref","first-page":"156","DOI":"10.1159\/000111513","article-title":"Bortezomib-induced skin eruption","volume":"216","author":"Sanchez-Politta","year":"2008","journal-title":"Dermatology"},{"key":"10.1016\/j.jaad.2026.06.126_bib119","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1111\/j.1365-2141.2006.06201.x","article-title":"Drug-induced cutaneous vasculitis in patients with non-Hodgkin lymphoma treated with the novel proteasome inhibitor bortezomib: a possible surrogate marker of response?","volume":"134","author":"Gerecitano","year":"2006","journal-title":"Br J Haematol"},{"key":"10.1016\/j.jaad.2026.06.126_bib120","doi-asserted-by":"crossref","first-page":"e18","DOI":"10.1002\/phar.1383","article-title":"Bortezomib-induced Sweet's syndrome confirmed by rechallenge","volume":"34","author":"Zobniw","year":"2014","journal-title":"Pharmacotherapy"},{"key":"10.1016\/j.jaad.2026.06.126_bib121","doi-asserted-by":"crossref","first-page":"496","DOI":"10.1016\/j.jaad.2008.09.007","article-title":"Bortezomib-induced histiocytoid Sweet syndrome","volume":"60","author":"Murase","year":"2009","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.jaad.2026.06.126_bib122","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1111\/j.0902-4441.2005.t01-1-EJH2437.x","article-title":"Cutaneous leucoclastic vasculitis (LV) following bortezomib therapy in a myeloma patient; association with pro-inflammatory cytokines","volume":"76","author":"Min","year":"2006","journal-title":"Eur J Haematol"},{"key":"10.1016\/j.jaad.2026.06.126_bib123","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2023.1283247","article-title":"Post-marketing safety surveillance of sacituzumab govitecan: an observational, pharmacovigilance study leveraging FAERS database","volume":"14","author":"Liu","year":"2023","journal-title":"Front Pharmacol"},{"key":"10.1016\/j.jaad.2026.06.126_bib124","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0275321","article-title":"The adverse effects of trastuzumab-containing regimes as a therapy in breast cancer: a piggy-back systematic review and meta-analysis","volume":"17","author":"Jackson","year":"2022","journal-title":"PLoS One"},{"key":"10.1016\/j.jaad.2026.06.126_bib125","doi-asserted-by":"crossref","DOI":"10.1016\/j.breast.2024.103853","article-title":"Safety profile of sacituzumab govitecan in patients with breast cancer: a systematic review and meta-analysis","volume":"79","author":"Dacoregio","year":"2025","journal-title":"Breast"},{"key":"10.1016\/j.jaad.2026.06.126_bib126","article-title":"Toxicity profile of antibody-drug conjugates in breast cancer: practical considerations","volume":"62","author":"D'Arienzo","year":"2023","journal-title":"EClinicalMedicine"},{"key":"10.1016\/j.jaad.2026.06.126_bib127","doi-asserted-by":"crossref","first-page":"741","DOI":"10.1056\/NEJMoa1814213","article-title":"Sacituzumab Govitecan-hziy in refractory metastatic triple-negative breast cancer","volume":"380","author":"Bardia","year":"2019","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jaad.2026.06.126_bib128","doi-asserted-by":"crossref","first-page":"1229","DOI":"10.1016\/S1470-2045(18)30426-1","article-title":"Brentuximab vedotin with gemcitabine for paediatric and young adult patients with relapsed or refractory Hodgkin's lymphoma (AHOD1221): a Children's Oncology Group, multicentre single-arm, phase 1-2 trial","volume":"19","author":"Cole","year":"2018","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.jaad.2026.06.126_bib129","doi-asserted-by":"crossref","first-page":"617","DOI":"10.1080\/14740338.2020.1718103","article-title":"Risk of adverse events in lymphoma patients treated with brentuximab vedotin: a systematic review and meta-analysis","volume":"19","author":"Gao","year":"2020","journal-title":"Expert Opin Drug Saf"},{"key":"10.1016\/j.jaad.2026.06.126_bib130","doi-asserted-by":"crossref","first-page":"1131","DOI":"10.1097\/PAS.0000000000002268","article-title":"Histopathologic and clinical characterization of brentuximab vedotin-associated rash","volume":"48","author":"Narala","year":"2024","journal-title":"Am J Surg Pathol"},{"key":"10.1016\/j.jaad.2026.06.126_bib131","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1097\/DAD.0000000000002911","article-title":"Histopathologic comparison among drug eruptions induced by enfortumab vedotin, brentuximab vedotin, and taxanes","volume":"47","author":"Iwahashi","year":"2025","journal-title":"Am J Dermatopathol"},{"key":"10.1016\/j.jaad.2026.06.126_bib80","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1111\/cup.13911","article-title":"Cutaneous sarcoid-like drug reaction caused by an anaplastic lymphoma kinase inhibitor","volume":"48","author":"Gleue","year":"2021","journal-title":"J Cutan Pathol"},{"key":"10.1016\/j.jaad.2026.06.126_bib81","first-page":"403","article-title":"Crizotinib-induced lichenoid drug eruption in a patient with lung cancer","volume":"102","author":"Ho","year":"2018","journal-title":"Cutis"},{"key":"10.1016\/j.jaad.2026.06.126_bib82","first-page":"73","article-title":"Hypersensitivity in ALK-positive lung cancers exposed to ALK inhibitors: a case of successful switch to an alternative ALK inhibitor and systematic review of the literature","volume":"9","author":"Deng","year":"2018","journal-title":"Lung Cancer (Auckl)"},{"key":"10.1016\/j.jaad.2026.06.126_bib83","doi-asserted-by":"crossref","first-page":"1296","DOI":"10.21037\/apm.2019.08.05","article-title":"Cutaneous toxicities of new targeted cancer therapies: must know for diagnosis, management, and patient-proxy empowerment","volume":"9","author":"McFarlane","year":"2020","journal-title":"Ann Palliat Med"},{"key":"10.1016\/j.jaad.2026.06.126_bib84","doi-asserted-by":"crossref","first-page":"4940","DOI":"10.3390\/cancers15204940","article-title":"Anaplastic lymphoma kinase inhibitor-induced neutropenia: a systematic review","volume":"15","author":"Moinard-Butot","year":"2023","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.jaad.2026.06.126_bib132","series-title":"Lumakras (Sotorasib) [Package Insert]","year":"2021"},{"key":"10.1016\/j.jaad.2026.06.126_bib133","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1111\/j.1468-3083.2012.04546.x","article-title":"Cutaneous side effects of inhibitors of the RAS\/RAF\/MEK\/ERK signalling pathway and their management","volume":"27","author":"Manousaridis","year":"2013","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"10.1016\/j.jaad.2026.06.126_bib134","series-title":"Vitrakvi (Larotrectinib) [Package Insert]","year":"2018"},{"key":"10.1016\/j.jaad.2026.06.126_bib135","series-title":"Rozlytrek (Entrectinib) [Package Insert]","year":"2019"},{"key":"10.1016\/j.jaad.2026.06.126_bib136","series-title":"Augtyro (Repotrectinib) [Package Insert]","year":"2023"},{"key":"10.1016\/j.jaad.2026.06.126_bib137","doi-asserted-by":"crossref","first-page":"705","DOI":"10.1016\/S1470-2045(18)30119-0","article-title":"Larotrectinib for paediatric solid tumours harbouring NTRK gene fusions: phase 1 results from a multicentre, open-label, phase 1\/2 study","volume":"19","author":"Laetsch","year":"2018","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.jaad.2026.06.126_bib138","first-page":"471","article-title":"Quantifying cutaneous adverse effects of systemic glucocorticoids in patients with rheumatoid arthritis: a cross-sectional cohort study","volume":"35","author":"Amann","year":"2017","journal-title":"Clin Exp Rheumatol"},{"key":"10.1016\/j.jaad.2026.06.126_bib139","doi-asserted-by":"crossref","first-page":"1119","DOI":"10.1136\/ard.2008.092163","article-title":"Dose-related patterns of glucocorticoid-induced side effects","volume":"68","author":"Huscher","year":"2009","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.jaad.2026.06.126_bib140","doi-asserted-by":"crossref","first-page":"611","DOI":"10.1016\/S2213-8587(16)00086-3","article-title":"Complications of Cushing's syndrome: state of the art","volume":"4","author":"Pivonello","year":"2016","journal-title":"Lancet Diabetes Endocrinol"},{"key":"10.1016\/j.jaad.2026.06.126_bib141","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1111\/j.1365-2133.2007.07950.x","article-title":"Corticosteroid-induced clinical adverse events: frequency, risk factors and patient's opinion","volume":"157","author":"Fardet","year":"2007","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.jaad.2026.06.126_bib142","doi-asserted-by":"crossref","first-page":"e2","DOI":"10.1136\/archdischild-2015-309522","article-title":"Long-course oral corticosteroid toxicity in children","volume":"101","author":"Aljebab","year":"2016","journal-title":"Arch Dis Child"},{"key":"10.1016\/j.jaad.2026.06.126_bib143","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0170259","article-title":"Systematic review of the toxicity of long-course oral corticosteroids in children","volume":"12","author":"Aljebab","year":"2017","journal-title":"PLoS One"},{"key":"10.1016\/j.jaad.2026.06.126_bib144","doi-asserted-by":"crossref","first-page":"1249","DOI":"10.1016\/S1470-2045(22)00507-1","article-title":"Rezvilutamide versus bicalutamide in combination with androgen-deprivation therapy in patients with high-volume, metastatic, hormone-sensitive prostate cancer (CHART): a randomised, open-label, phase 3 trial","volume":"23","author":"Gu","year":"2022","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.jaad.2026.06.126_bib145","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1016\/S0022-5347(05)64652-6","article-title":"Bicalutamide as immediate therapy either alone or as adjuvant to standard care of patients with localized or locally advanced prostate cancer: first analysis of the early prostate cancer program","volume":"168","author":"See","year":"2002","journal-title":"J Urol"},{"key":"10.1016\/j.jaad.2026.06.126_bib146","doi-asserted-by":"crossref","first-page":"525","DOI":"10.1080\/02841860701291698","article-title":"Effect of adjuvant systemic treatment on cosmetic outcome and late normal-tissue reactions after breast conservation","volume":"46","author":"Johansen","year":"2007","journal-title":"Acta Oncol"},{"key":"10.1016\/j.jaad.2026.06.126_bib147","article-title":"Evaluation of dermatologic adverse events associated with aromatase inhibitors: insights from the FAERS database","volume":"16","author":"Wu","year":"2025","journal-title":"Front Pharmacol"},{"key":"10.1016\/j.jaad.2026.06.126_bib148","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1080\/14740338.2025.2499218","article-title":"Safety profile of letrozole in the real world: a disproportionality analysis of FAERS database and systematic review of case reports","author":"Liang","year":"2025","journal-title":"Expert Opin Drug Saf"}],"container-title":["Journal of the American Academy of Dermatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0190962226030239?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0190962226030239?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,10,27]],"date-time":"2026-10-27T21:29:57Z","timestamp":1793136597000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0190962226030239"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,11]]},"references-count":148,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2026,11]]}},"alternative-id":["S0190962226030239"],"URL":"https:\/\/doi.org\/10.1016\/j.jaad.2026.06.126","relation":{},"ISSN":["0190-9622"],"issn-type":[{"value":"0190-9622","type":"print"}],"subject":[],"published":{"date-parts":[[2026,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Perioperative management of dermatologic surgery patients on systemic cancer therapy","name":"articletitle","label":"Article Title"},{"value":"Journal of the American Academy of Dermatology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jaad.2026.06.126","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 by the American Academy of Dermatology, Inc.","name":"copyright","label":"Copyright"}]}}